All Oncology News

The addition of ipilimumab to cabozantinib plus nivolumab was safe and showed notable efficacy in patients with rare genitourinary cancers.

Aaron Gerds, MD discusses updated efficacy findings from the prospective randomized phase 3 MANIFEST-2 trial.

IDE937 produced responses in patients with advanced urothelial cancer or non–small cell lung cancer harboring MTAP deletions.

Francisco Hernandez-Ilizaliturri, MD, details factors that influence CAR T-cell therapy selection in relapsed/refractory follicular lymphoma.

The investigational menin-MLL inhibitor DSP-5336 has received FDA fast track designation in KMT2A-rearranged/NPM1-mutant acute myeloid leukemia.

Moleculin Biotech completed an end-of-phase 2 meeting with the FDA regarding the investigation of annamycin plus cytarabine in acute myeloid leukemia.

Tycel Phillips, MD, expands on the treatment paradigm for patients with mantle cell lymphoma, highlighting recent data read-outs and FDA approvals/withdrawals

Pamela J Sung, MD, PhD, details differentiation therapy in acute myeloid leukemia, focusing on newer targets and preclinical evidence for a novel FLT3 combination.

Preliminary data from a first-in-human phase 1 trial using a CAR T-cell therapy developed by City of Hope researchers has been published in Nature Medicine.

Natural killer cells hold promise for treating cancer; Yale researchers have found a way to overcome their main limitation.

The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.

Ciara Kelly, MBBCh, BAO, discusses ongoing GIST research for GIST Awareness Day.

Belzutifan generated superior efficacy and safety outcomes vs everolimus across prespecified subgroups of patients with previously treated advanced ccRCC.

Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.

Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.

Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.

Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.

Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.

Health Canada has approved osimertinib/chemotherapy for advanced non–small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations.

Grzegorz S. Nowakowski, MD, discusses the accelerated approval of epcoritamab in follicular lymphoma, touching on key trial data and remaining unmet needs.

The HHS competition evaluated the effectiveness of Ochsner Connected MOM in increasing blood pressure monitoring during pregnancy and the postpartum period.

As the lung cancer paradigm continues to advance, increasingly effective therapies are under development for previously underserved disease subtypes.

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.

Frontline eftilagimod alpha plus pembrolizumab was safe and elicited responses in patients with PD-L1–negative head and neck squamous cell carcinoma.

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.

Aaron Gerds, MD, discusses progression data for patients with low- or intermediate-1–risk myelofibrosis in the MOST trial.

Research team shares new data on how XPO1 blockade may boost immune-based treatments.